Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia® Connect Infusion System with Vigilant® Software Suite-Vigilant® Master Med Technology

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration for its wireless Agilia® Connect Infusion System which includes the Agilia® Volumetric Pump and the Agilia® Syringe Pump with Vigilant® Software Suite-Vigilant® Master Med technology.

The Agilia Connect volumetric pump and syringe pump are the first to be cleared by following TIR101 standards, which were developed by the Association for the Advancement of Medical Instrumentation (AAMI) in 2021.

The wireless Agilia Connect Infusion System has been available outside the U.S. since 2016 and has more than 126,000 customer installations. The Agilia Connect Infusion System builds on the company’s first generation Agilia Infusion System, available in more than 130 countries with more than 1.2 million customer installations, to provide wireless connectivity through the Vigilant Software Suite. This software suite includes Vigilant Master Med drug library software, Vigilant Insight infusion analytics software and Agilia Partner calibration and maintenance software. The product offering enables the centralized distribution of drug libraries, warehousing of infusion data for reporting and analysis and wireless maintenance and calibration of devices.

“Both patients and caregivers benefit from smarter devices that make health care safer and easier,” said John Ducker, president and CEO of Fresenius Kabi USA. “As a company with more than 35 years of global infusion technology expertise we look forward to establishing Fresenius Kabi as the partner of choice for infusion therapy in the U.S.”

Focused on patient safety and designed to drive best practices, Agilia features customized Master Drug Libraries based on each hospital or clinic’s approved medication protocols. These drug libraries can be distributed wirelessly to an entire fleet of Agilia Connect Pumps, safely and securely. With the Vigilant Insight Continuous Quality Improvement software, infusion data can be configured on demand into reports. This enables providers to conduct independent performance analyses across multiple health care facilities to help reach their infusion practice and patient safety goals.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy